On Dec. 1, 2021, SIGA Technologies announced that Health Canada had approved oral TPOXX (tecovirimat) as an extraordinary use new drug. Specifically, Health Canada authorized the use of oral TPOXX for the treatment of human smallpox disease in adults and pediatric patients weighing at least 13 kg.

TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in Jul. 2018.